Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Soft Tissue Infections 1Lymphoma, Follicular 1Infections 1Fournier Gangrene 1Fasciitis, Necrotizing 1

Interventions

Rituximab 1401Cyclophosphamide 1306Vincristine 668Doxorubicin 587Etoposide 527Prednisone 511Cytarabine 486fludarabine 470Methotrexate 445Dexamethasone 413fludarabine phosphate 400Lenalidomide 356Filgrastim 343Bendamustine Hydrochloride 282Radiotherapy 267venetoclax 261ibrutinib 258obinutuzumab 236Peripheral Blood Stem Cell Transplantation 234Melphalan 230Granulocyte Colony-Stimulating Factor 215Bortezomib 204Gemcitabine 202Busulfan 188Whole-Body Irradiation 187Mycophenolic Acid 175Tacrolimus 165Specimen Handling 162Magnetic Resonance Spectroscopy 155Calcium Dobesilate 150

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Daptomycin × Lymphoid × Clear all
NCT00261807 2022-01-27

Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections

University of Maryland, Baltimore

Phase NA Completed
25 enrolled 7 charts
Lymphoid

Infections, Lymphoma, Follicular, Soft Tissue Infections, Fournier Gangrene, Fasciitis, Necrotizing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡